DÄ internationalArchiveReferences

Review article

The Diagnosis and Treatment of Sjögren’s Syndrome

Dtsch Arztebl Int 2017; 114: 354-61. DOI: 10.3238/arztebl.2017.0354

Stefanski, AL; Tomiak, C; Pleyer, U; Dietrich, T; Burmester, G R; Dörner, T

1. Tomiak C, Dorner T: Sjogren‘s syndrome. Current aspects from a rheumatological point of view. Z Rheumatol 2006; 65: 505–17 CrossRef MEDLINE
2.Qin B, Wang J, Yang Z, et al.: Epidemiology of primary Sjögren‘s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 1983–9 CrossRef MEDLINE
3.Westhoff G, Zink A: Epidemiology of primary Sjogren‘s syndrome. Z Rheumatol 2010; 69: 41–9 CrossRef MEDLINE
4.Brito-Zeron P, Theander E, Baldini C, et al.: Early diagnosis of primary Sjögren‘s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 2016; 12: 137–56 CrossRef MEDLINE
5.Fox PC, Bowman SJ, Segal B, et al.: Oral involvement in primary Sjögren syndrome. J Am Dent Assoc 2008; 139: 1592–601 CrossRef MEDLINE
6.Bron AJ, Tomlinson A, Foulks GN, et al.: Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf 2014; 12: 1–31 CrossRef MEDLINE
7.Villa A, Abati S: Risk factors and symptoms associated with xerostomia: a cross-sectional study. Aust Dent J 2011; 56: 290–5 CrossRef MEDLINE
8. Cornec D, Saraux A, Jousse-Joulin S, et al.: The differential diagnosis of dry eyes, dry mouth, and parotidomegaly: a comprehensive review. Clin Rev Allergy Immunol 2015; 49: 278–87 CrossRef MEDLINE
9.Ramos-Casals M, Brito-Zeron P, Solans R, et al.: Systemic involvement in primary Sjögren‘s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 2014; 53: 321–31 CrossRef MEDLINE
10. Nishishinya MB, Pereda CA, Munoz-Fernandez S, et al.: Identification of lymphoma predictors in patients with primary Sjögren‘s syndrome: a systematic literature review and meta-analysis. Rheumatol Int 2015; 35: 17–26 CrossRef MEDLINE
11.Theander E, Vasaitis L, Baecklund E, et al.: Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren‘s syndrome. Ann Rheum Dis 2011; 70: 1363–8 CrossRef MEDLINE PubMed Central
12.Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S: Pulmonary manifestations of Sjögren‘s syndrome. Eur Respir Rev 2016; 25: 110–23 CrossRef MEDLINE
13.Evans R, Zdebik A, Ciurtin C, Walsh SB: Renal involvement in primary Sjögren‘s syndrome. Rheumatology (Oxford) 2015; 549: 1541–8 CrossRef MEDLINE
14.Pavlakis PP, Alexopoulos H, Kosmidis ML, et al.: Peripheral neuropathies in Sjögren‘s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun 2012; 39: 27–33 CrossRef MEDLINE
15. Harms L, Hiepe F: Neurological manifestations in connective tissue disease. Z Rheumatol 2012; 71: 564–71 CrossRef MEDLINE
16.Westhoff G, Dörner T, Zink A: Fatigue and depression predict physician visits and work disability in women with primary Sjogren‘s syndrome: results from a cohort study. Rheumatology (Oxford) 2012; 51: 262–9 CrossRef MEDLINE
17.Brito-Zeron P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA: The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015; 11: 301–12 MEDLINE MEDLINE
18.Singh AG, Singh S, Matteson EL: Rate, risk factors and causes of mortality in patients with Sjögren‘s syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2016; 55: 450–60.
19.Moutsopoulos HM: Sjögren‘s Syndrome: autoimmune epithelitis. Clinical Immunology and Immunopathology 1994; 72: 162–5 CrossRef
20.Shiboski CH, Shiboski SC, Seror R, et al.: 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren‘s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017; 69: 35–45 CrossRef MEDLINE
21.Cornec D, Devauchelle-Pensec V, Saraux A, Jousse-Joulin S: Clinical usefulness of salivary gland ultrasonography in Sjögren‘s syndrome: where are we now? Rev Med Interne 2016; 37: 186–94 CrossRef MEDLINE
22.Nardi N, Brito-Zeron P, Ramos-Casals M, et al.: Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren‘s syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol 2006; 25: 341–6 CrossRef MEDLINE
23.Pisetsky DS: Antinuclear antibodies in healthy people: the tip of autoimmunity‘s iceberg? Arthritis Res Ther 2011; 13: 109 CrossRef MEDLINE PubMed Central
24.Patel R, Shahane A: The epidemiology of Sjögren‘s syndrome. Clin Epidemiol 2014; 6: 247–55 MEDLINE PubMed Central
25.Theander E, Jonsson R, Sjostrom B, Brokstad K, Olsson P, Henriksson G: Prediction of Sjögren‘s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol 2015; 67: 2427–36 CrossRef MEDLINE
26.Gottenberg JE, Seror R, Miceli-Richard C, et al.: Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren‘s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013; 8: e59868 CrossRef MEDLINE PubMed Central
27.Rose T, Szelinski F, Lisney A, et al.: SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren‘s syndrome. RMD Open 2016; 2: e000292 CrossRef MEDLINE PubMed Central
28.Daniels TE, Cox D, Shiboski CH, et al.: Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren‘s syndrome among 1,726 registry participants. Arthritis Rheum 2011; 63: 2021–30 CrossRef MEDLINE PubMed Central
29.Seror R, Bowman SJ, Brito-Zeron P, et al.: EULAR Sjögren‘s syndrome disease activity index (ESSDAI): a user guide. RMD Open 2015; 1: e000022 CrossRef MEDLINE PubMed Central
30.Saraux A, Pers JO, Devauchelle-Pensec V: Treatment of primary Sjögren syndrome. Nat Rev Rheumatol 2016; 12: 456–71 CrossRef MEDLINE
31.Leonardi A, Van Setten G, Amrane M, et al.: Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 2016; 26: 287–96 CrossRef MEDLINE
32.Romero-Rangel T, Stavrou P, Cotter J, Rosenthal P, Baltatzis S, Foster CS: Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 2000; 130: 25–32 CrossRef
33.Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R: Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 2011; (12): CD008934 CrossRef
34.Furness S, Bryan G, McMillan R, Worthington HV: Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev 2013; (8): CD009603 CrossRef
35.Albrecht K, Callhoff J, Westhoff G, Dietrich T, Dorner T, Zink A: The prevalence of dental implants and related factors in patients with Sjogren syndrome: results from a cohort study. J Rheumatol 2016; 43: 1380–5 CrossRef MEDLINE
36.Carsons SE, Vivino FB, Parke A, et al.: Treatment guidelines for rheumatologic manifestations of Sjogren‘s: use of biologics, management of fatigue and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken) 2016.
37.Gottenberg JE, Ravaud P, Puechal X, et al.: Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014; 312: 249–58 CrossRef MEDLINE
38.Dass S, Bowman SJ, Vital EM, et al.: Reduction of fatigue in Sjögren’s syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis 2008; 67: 1541–4 CrossRef MEDLINE
39.Bowman S, Everett C, Bombardieri M, et al.: Preliminary results of a double-blind randomised trial of rituximab anti-B-cell therapy in patients with primary Sjogrens syndrome. Arthritis Rheumatol 2015; 67: 3955–7.
40. Izmirly PM, Kim MY, Llanos C, et al.: Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010; 6910: 1827–30 CrossRef MEDLINE PubMed Central
e1. Segal BM, Pogatchnik B, Holker E, et al.: Primary Sjogren’s syndrome: cognitive symptoms, mood, and cognitive performance. Acta Neurol Scand 2012; 125: 272–8 CrossRef MEDLINE PubMed Central
e2. Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM: HLA and Sjögren‘s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 2012; 11: 281–7 CrossRef MEDLINE
e3.Reksten TR, Lessard CJ, Sivils KL: Genetics in Sjögren syndrome. Rheum Dis Clin North Am 2016; 42: 435–47 CrossRef MEDLINE
e4.Hall JC, Baer AN, Shah AA, et al.: Molecular subsetting of interferon pathways in Sjögren’s syndrome. Arthritis Rheumatol 2015; 67: 2437–46 CrossRef MEDLINE PubMed Central
e5.Mavragani CP, Crow MK: Activation of the type I interferon pathway in primary Sjögren‘s syndrome. J Autoimmun 2010; 35: 225–31 CrossRef MEDLINE
e6.Hansen A, Dörner T: Sjögren syndrom. Internist (Berl) 2010; 51: 1267–79 CrossRef MEDLINE
e7.Seror R, Theander E, Brun JG, et al.: Validation of EULAR primary Sjögren‘s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015; 74: 859–66 CrossRef MEDLINE